2 results
Approved WMOCompleted
Primary: Safety and tolerability.Secondary: Clinical and endoscopic remission, symptomatic clinical remission, clinical response, mucosal healing, health related QoL, CRP, faecal calprotectin, pharmacokinetics.
Approved WMOCompleted
Primary objectives1. What is the effect of stopping mesalazine in the maintenance setting of patients with quiescent CD?2. Can subgroups of CD patients, for example based on prior treatment (medical vs. surgical), localization of disease, diseaseā¦